PITTSBURGH, PA – October 6, 2022 — Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 tr

The CEO, founder and president of Peptilogics is changing the game for the peptide medicine space with a promising pipeline and a disruptive discovery platform. Published Sept. 6, 2022 Meagan ParrishLead Editor Permissio

PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of periprosthetic joint infection Pittsburgh, PA [ July 19, 2022]: Peptilogics, a biotech company engineering peptide therapeutics